Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery

Young Sun Lee, Ha Seok Lee, Sung Won Chang, Chan Uk Lee, Jung Sun Kim, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Chang Hee Lee, Sang Uk Woo, Jae Hong Seo, Jong Eun Yeon, Soon Ho Um, Kwan Soo Byun

Research output: Contribution to journalArticle

Abstract

Breast cancer is the most common cancer among women worldwide, and it is a main cause of death in women. As with breast cancer, metabolic components are important risk factors for the development of nonalcoholic fatty liver disease (NAFLD). In this retrospective cohort study, we aimed to determine the prevalence of NAFLD in patients with breast cancer and the impact of NAFLD on the prognosis of breast cancer.Patients with breast cancer were enrolled in the study from January 2007 to June 2017. Hepatic steatosis was evaluated through non-enhanced computed tomography scan by measuring Hounsfield Units in the liver and spleen, respectively; 123 healthy controls who underwent non-enhanced computed tomography scan were also analyzed.The prevalence of NAFLD in patients with breast cancer was 15.8% (251/1587), which was significantly higher than in healthy controls (8.9%, 11/123) (P = .036). Overall survival did not significantly differ between the groups with and without NAFLD (P = .304). However, recurrence-free survival was significantly higher in patients without NAFLD than in those with NAFLD (P = .009). Among breast cancer patients receiving endocrine treatment, the NAFLD group showed a higher cumulative incidence of significant liver injury than the group without NAFLD (P < .001).The prevalence of NAFLD in patients with breast cancer is significantly higher than in healthy controls. Moreover, breast cancer patients with NAFLD showed poorer prognosis in terms of recurrence. Therefore, diagnostic evaluation for NALFD is important in managing patients with breast cancer.

Original languageEnglish
Article numbere17277
JournalMedicine (United States)
Volume98
Issue number39
DOIs
Publication statusPublished - 2019 Sep 1

Fingerprint

Breast Neoplasms
Recurrence
Liver
Non-alcoholic Fatty Liver Disease
Tomography
Survival
Cause of Death
Cohort Studies
Spleen
Retrospective Studies
Incidence
Wounds and Injuries
Neoplasms

Keywords

  • breast cancer
  • nonalcoholic fatty liver disease
  • prognosis
  • recurrence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{d35584fb2c9a494b8c59c487872bfbbb,
title = "Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery",
abstract = "Breast cancer is the most common cancer among women worldwide, and it is a main cause of death in women. As with breast cancer, metabolic components are important risk factors for the development of nonalcoholic fatty liver disease (NAFLD). In this retrospective cohort study, we aimed to determine the prevalence of NAFLD in patients with breast cancer and the impact of NAFLD on the prognosis of breast cancer.Patients with breast cancer were enrolled in the study from January 2007 to June 2017. Hepatic steatosis was evaluated through non-enhanced computed tomography scan by measuring Hounsfield Units in the liver and spleen, respectively; 123 healthy controls who underwent non-enhanced computed tomography scan were also analyzed.The prevalence of NAFLD in patients with breast cancer was 15.8{\%} (251/1587), which was significantly higher than in healthy controls (8.9{\%}, 11/123) (P = .036). Overall survival did not significantly differ between the groups with and without NAFLD (P = .304). However, recurrence-free survival was significantly higher in patients without NAFLD than in those with NAFLD (P = .009). Among breast cancer patients receiving endocrine treatment, the NAFLD group showed a higher cumulative incidence of significant liver injury than the group without NAFLD (P < .001).The prevalence of NAFLD in patients with breast cancer is significantly higher than in healthy controls. Moreover, breast cancer patients with NAFLD showed poorer prognosis in terms of recurrence. Therefore, diagnostic evaluation for NALFD is important in managing patients with breast cancer.",
keywords = "breast cancer, nonalcoholic fatty liver disease, prognosis, recurrence",
author = "Lee, {Young Sun} and Lee, {Ha Seok} and Chang, {Sung Won} and Lee, {Chan Uk} and Kim, {Jung Sun} and Jung, {Young Kul} and Kim, {Ji Hoon} and Seo, {Yeon Seok} and Yim, {Hyung Joon} and Lee, {Chang Hee} and Woo, {Sang Uk} and Seo, {Jae Hong} and Yeon, {Jong Eun} and Um, {Soon Ho} and Byun, {Kwan Soo}",
year = "2019",
month = "9",
day = "1",
doi = "10.1097/MD.0000000000017277",
language = "English",
volume = "98",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "39",

}

TY - JOUR

T1 - Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery

AU - Lee, Young Sun

AU - Lee, Ha Seok

AU - Chang, Sung Won

AU - Lee, Chan Uk

AU - Kim, Jung Sun

AU - Jung, Young Kul

AU - Kim, Ji Hoon

AU - Seo, Yeon Seok

AU - Yim, Hyung Joon

AU - Lee, Chang Hee

AU - Woo, Sang Uk

AU - Seo, Jae Hong

AU - Yeon, Jong Eun

AU - Um, Soon Ho

AU - Byun, Kwan Soo

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Breast cancer is the most common cancer among women worldwide, and it is a main cause of death in women. As with breast cancer, metabolic components are important risk factors for the development of nonalcoholic fatty liver disease (NAFLD). In this retrospective cohort study, we aimed to determine the prevalence of NAFLD in patients with breast cancer and the impact of NAFLD on the prognosis of breast cancer.Patients with breast cancer were enrolled in the study from January 2007 to June 2017. Hepatic steatosis was evaluated through non-enhanced computed tomography scan by measuring Hounsfield Units in the liver and spleen, respectively; 123 healthy controls who underwent non-enhanced computed tomography scan were also analyzed.The prevalence of NAFLD in patients with breast cancer was 15.8% (251/1587), which was significantly higher than in healthy controls (8.9%, 11/123) (P = .036). Overall survival did not significantly differ between the groups with and without NAFLD (P = .304). However, recurrence-free survival was significantly higher in patients without NAFLD than in those with NAFLD (P = .009). Among breast cancer patients receiving endocrine treatment, the NAFLD group showed a higher cumulative incidence of significant liver injury than the group without NAFLD (P < .001).The prevalence of NAFLD in patients with breast cancer is significantly higher than in healthy controls. Moreover, breast cancer patients with NAFLD showed poorer prognosis in terms of recurrence. Therefore, diagnostic evaluation for NALFD is important in managing patients with breast cancer.

AB - Breast cancer is the most common cancer among women worldwide, and it is a main cause of death in women. As with breast cancer, metabolic components are important risk factors for the development of nonalcoholic fatty liver disease (NAFLD). In this retrospective cohort study, we aimed to determine the prevalence of NAFLD in patients with breast cancer and the impact of NAFLD on the prognosis of breast cancer.Patients with breast cancer were enrolled in the study from January 2007 to June 2017. Hepatic steatosis was evaluated through non-enhanced computed tomography scan by measuring Hounsfield Units in the liver and spleen, respectively; 123 healthy controls who underwent non-enhanced computed tomography scan were also analyzed.The prevalence of NAFLD in patients with breast cancer was 15.8% (251/1587), which was significantly higher than in healthy controls (8.9%, 11/123) (P = .036). Overall survival did not significantly differ between the groups with and without NAFLD (P = .304). However, recurrence-free survival was significantly higher in patients without NAFLD than in those with NAFLD (P = .009). Among breast cancer patients receiving endocrine treatment, the NAFLD group showed a higher cumulative incidence of significant liver injury than the group without NAFLD (P < .001).The prevalence of NAFLD in patients with breast cancer is significantly higher than in healthy controls. Moreover, breast cancer patients with NAFLD showed poorer prognosis in terms of recurrence. Therefore, diagnostic evaluation for NALFD is important in managing patients with breast cancer.

KW - breast cancer

KW - nonalcoholic fatty liver disease

KW - prognosis

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=85072848179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072848179&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000017277

DO - 10.1097/MD.0000000000017277

M3 - Article

C2 - 31574842

AN - SCOPUS:85072848179

VL - 98

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 39

M1 - e17277

ER -